secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-10-11T23:59:59+00:00
Accession:  0001447028-24-000084
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CSO Michael J. Sofia to retire Dec 31, 2024; amendment clarifies severance and non-compete
--------------------------------------------------------------------------------

- CSO Michael J. Sofia will retire effective December 31, 2024; amendment to employment agreement dated Oct 11, 2024.
- Sofia eligible for 2024 annual target cash bonus ($204,800) prorated by corporate score, payable ~Feb 15, 2025.
- Amendment carves out coronavirus and HDV-only treatments from non-compete; also allows academic teaching/research.
- Sofia must sign release to receive benefits; 21-day consideration period and 7-day revocation.
- No named replacement; retirement is planned, not abrupt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000144702824000084/0001447028-24-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000144702824000084/abus-20241011.htm
  HTML page:      https://secwatch.observer/filing/0001447028-24-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer